Skip to main content

Arcturus Therapeutics Holdings Inc.

ARCT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001768224

No open-market purchases or sales by Arcturus Therapeutics Holdings Inc. insiders were filed in the last 90 days; 154 institutions reported holding it in 13F filings for Q3 2026, worth $345.6M in total; ARK Invest is the only superinvestor holding it.

Key figures

Market capClose on Nov 20, 2026
$214.7M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ3 2026, +18 vs. previous quarter
154
13F valueReported value at the end of Q3 2026
$345.6M
Superinvestors holdingAt the end of Q3 2026
1

Price chart

From SEC filings, in USD.

Revenue, FY2025
$82.0M
−46.1% year over year
Net income, FY2025
-$65.8M
No comparable prior period
Free cash flow, FY2025
-$74.5M
No comparable prior period
Revenue, Q3 FY2026
$18.3M
+6.7% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $65.8M (80.2% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
5.41M
Shares sold short
Change
−50.5K
−0.9% vs. previous
Days to cover
7.37
At average daily volume

Superinvestors holding ARCT, Q3 2026

Go to the superinvestors tab

1 superinvestor reports holding Arcturus Therapeutics Holdings Inc. on Form 13F. Percentages are the stock's share of each portfolio.

ARK Invest

Cathie Wood

0.2%

Arcturus Therapeutics Holdings Inc.'s share of the portfolio

Shares
2,994,550
Value
$41.0M

Latest insider trades

See all insider trades

Open-market purchases and sales by Arcturus Therapeutics Holdings Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 20, 2025 (view filing)Aug 155 daysSassine AndyChief Financial OfficerPPurchase+1.24K$16.56+$20.5K+0.6%221.8K afterAmended
Oct 16, 2024 (view filing)Oct 151 dayChivukula PadChief Scientific Officer & COOSSale−12.0K$20.76−$249.1K−2.7%435.3K after10b5-1
Jun 14, 2024 (view filing)Jun 122 daysSassine AndyChief Financial OfficerSSale−50.0K$32.03−$1.60M−18.5%220.5K after
Jun 7, 2024 (view filing)Jun 52 daysChivukula PadChief Scientific Officer & COOSSale−114$45.00−$5.13K0.0%447.3K after10b5-1
Jun 4, 2024 (view filing)Jun 31 dayChivukula PadChief Scientific Officer & COOSSale−26.0K$40.01−$1.04M−5.5%447.4K after10b5-1
Mar 27, 2024 (view filing)Mar 252 daysChivukula PadChief Scientific Officer & COOSSale−17.4K$35.02−$610.6K−3.6%473.4K after10b5-1
Mar 21, 2024 (view filing)Mar 192 daysChivukula PadChief Scientific Officer & COOSSale−8.56K$35.01−$299.9K−1.7%490.9K after10b5-1
Nov 3, 2023 (view filing)Nov 12 daysChivukula PadChief Scientific Officer & COOSSale−5.00K$18.72−$93.6K−1.0%499.4K after10b5-1
Oct 4, 2023 (view filing)Oct 22 daysChivukula PadChief Scientific Officer & COOSSale−5.00K$25.61−$128.1K−1.0%504.4K after10b5-1
Sep 5, 2023 (view filing)Sep 14 daysChivukula PadChief Scientific Officer & COOSSale−5.00K$31.45−$157.3K−1.0%509.4K after10b5-1

Top 10 13F holders, Q3 2026

See all 154 holders

The largest institutional positions in Arcturus Therapeutics Holdings Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding ARCT in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
ARK Investment Management LLCSuperinvestorARK Invest2,994,550$41.0M0.24%+92,915+3.2%Added
BlackRock, Inc.2,694,816$36.9M0.00%+80,804+3.1%Added
Sumitomo Mitsui Trust Holdings, Inc.1,689,107$23.1M0.01%−274,016−14.0%Reduced
Nikko Asset Management Americas, Inc.1,689,107$23.1M0.29%−271,351−13.8%Reduced
Federated Hermes, Inc.1,678,069$23.0M0.03%−1,625,571−49.2%Reduced
Two Sigma Investments, LP1,231,847$16.9M0.01%+140,710+12.9%Added
Vanguard Capital Management LLC1,107,056$15.2M0.00%−7,900−0.7%Reduced
D. E. Shaw & Co., Inc.976,120$13.4M0.01%+583,762+148.8%Added
Vanguard Portfolio Management LLC861,240$11.8M0.00%−90,335−9.5%Reduced
Jacobs Levy Equity Management, Inc703,060$9.62M0.03%+55,549+8.6%Added

Holders of 5% or more of ARCT

See all 6 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Arcturus Therapeutics Holdings Inc..

Largest holders of ARCT from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
ARK Investment Management LLCSuperinvestorARK Invest13G/A10.37%2.95M shares+1.18 ppfrom 9.19%Feb 16, 20218 filingsMay 7, 2026SEC
Meiji Seika Pharma Co., Ltd.13G7.88%2.47M sharesNewNov 18, 20261 filingNov 18, 2026SEC
BlackRock, Inc.13G/A7.80%2.10M shares–Apr 23, 20251 filingApr 23, 2025SEC
Nikko Asset Management Americas, Inc.13G/A5.90%1.69M shares−1.30 ppfrom 7.20%Feb 14, 20227 filingsNov 13, 2026SEC
Sumitomo Mitsui Trust Holdings, Inc.13G/A5.90%1.69M shares−1.30 ppfrom 7.20%Feb 4, 20227 filingsOct 29, 2026SEC